The Food and Drug Administration has updated its patient screening guidance for use of the COVID-19 antiviral pill Paxlovid.
Paxlovid cuts seniors’ COVID-19 risk, no matter their vaccine status: study
By
Alicia Lasek (f3)
Jun 03, 2022
Both vaccinated and unvaccinated seniors with COVID-19 have lower rates of hospitalization and death when taking the antiviral pill Paxlovid, according to a new study from Israel.
Clinical briefs for Thursday, June 2
By
Alicia Lasek (f3)
Jun 02, 2022
Some docs reconsider Paxlovid use for mild COVID-19 cases … Department of Labor releases new guidance and FAQs on mental health leave … Redefine long COVID in seniors as a “geriatric syndrome,”...
Paxlovid keeping hospitalizations, deaths low as COVID-19 infections rise, White House official says
By
Alicia Lasek (f3)
May 19, 2022
Clinicians are writing 20,000 prescriptions for Paxlovid each day, helping to keep severe outcomes in check, the COVID-19 Response Coordinator said Wednesday.
Rare cases of COVID-19 relapse seen with Pfizer pill
May 10, 2022
Reports of symptoms returning in patients several days after completing the five-day regimen of Paxlovid
Clinical briefs for Friday, May 6
By
Alicia Lasek (f3)
May 06, 2022
FDA official says “no evidence” second round of Paxlovid stops repeat symptoms, contradicting CEO … FDA planning for a “new normal”: annual COVID-19 and flu shots … Effect of COVID-19...
Clinical briefs for Tuesday, May 3
By
Alicia Lasek (f3)
May 03, 2022
Paxlovid does not prevent COVID-19, new trial data show … Black and white patients have had similar risk of MS for decades, study finds … Parkinson’s drug hopeful found safe in early clinical trial...
White House urges greater use of Paxlovid as supply increases
By
Alicia Lasek (f3)
Apr 28, 2022
Health officials are encouraging physicians to more frequently consider prescribing the oral antiviral now that it is no longer in short supply.
CDC: Turn to Paxlovid to treat COVID-19, not steroids or antibiotics
By
Alicia Lasek (f3)
Apr 26, 2022
The agency is urging clinicians to consider the now readily available, recommended therapies such as Paxlovid as first-line COVID-19 treatments.
WHO backs Paxlovid for milder COVID-19 cases; users tell of rebound symptoms
By
Alicia Lasek (f3)
Apr 25, 2022
The WHO’s guidance comes as some patients and clinicians report recurring symptoms after patients successfully finish a course of Paxlovid.